Medical Devices Australia

Australia Neuromodulation for Depression Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $15.6 Mn Placeholder estimate
Estimate 2025 $17.3 Mn 1.1% of the global market
Projected 2034 $45.0 Mn 160% Adds $27.7 Mn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 57% of 173 Medical Devices markets here
Key players 5
  • Australia is 1.1% of the global market.
  • In APAC, the largest is China at $119.2 Mn.
  • Fastest growing: India at 13.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$27.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $15.6 Mn — —
2025 (base) $17.3 Mn +$1.7 Mn —
2026 (forecast) $19.3 Mn +$1.9 Mn +11.2%
2027 (forecast) $21.4 Mn +$2.2 Mn +23.7%
2028 (forecast) $23.8 Mn +$2.4 Mn +37.5%
2029 (forecast) $26.5 Mn +$2.7 Mn +52.9%
2030 (forecast) $29.4 Mn +$3.0 Mn +70%
2031 (forecast) $32.7 Mn +$3.3 Mn +89.1%
2032 (forecast) $36.4 Mn +$3.7 Mn +110.2%
2033 (forecast) $40.5 Mn +$4.1 Mn +133.8%
2034 (forecast) $45.0 Mn +$4.5 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Neuromodulation for Depression Market Analysis at a glance
Market size, 2025$17.3 Mn placeholder estimate
Forecast, 2034$45.0 Mn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersNeuronetics, BrainsWay, Magstim, LivaNova PLC, Flow Neuroscience (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials1 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

Bar chart: Australia Neuromodulation for Depression market size, 2024–2034, placeholder estimates. $15.6 Mn in 2024, $17.3 Mn in 2025 and $45.0 Mn in 2034, 11.2% CAGR.
Australia Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in Australia

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in Australia

Neuromodulation for Depression in Australia: rules, payment and research

Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 1 study on Neuromodulation for Depression that is recruiting, active or about to start in Australia.⁠[3] Suicide rate: 13.2 per 100,000 people in 2023, the latest WHO figure for Australia.⁠[4]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

Australia compared

  • Suicide rate: 13.2 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuromodulation for Depression market in Australia?
Placeholder estimate: about $17.3 Mn in 2025, rising to about $45.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in Australia growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running in Australia?
1 study is recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
What does WHO report for Australia?
Suicide rate: 13.2 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Australia

See all

Related on mental health and brain and nerves

See the topic